The psychedelic therapy category has had a good few years in the press. Psilocybin made it to the cover of Time. MDMA-assisted therapy cleared Phase 3 trials (then hit complications with the FDA, a longer story). Ketamine is available in hundreds of clinics across the US right now. A lot of people discovering ibogaine arrive with a mental model shaped by what they've read about these other medicines.
That mental model is mostly wrong. Ibogaine is related to these therapies the way surgery is related to physical therapy: same general category of "medical intervention," very different experience.
The pharmacology is different
Psilocybin and LSD are primarily 5-HT2A agonists. They act on serotonin receptors and produce altered states characterized by perceptual changes, emotional amplification, and a kind of loosening of the default mode network (the brain's self-referential processing center) that creates openness and flexibility.
MDMA is an empathogen/entactogen. It floods the brain with serotonin, oxytocin, and dopamine, producing feelings of safety, warmth, and connection that make it easier to approach traumatic material without being overwhelmed by it.
Ketamine is a dissociative anesthetic, an NMDA receptor antagonist that produces a temporary disconnection from ordinary processing that can interrupt depressive states and, in some applications, create a window for therapeutic work.
Ibogaine is none of these things, exactly. It acts at sigma-2 receptors, NMDA receptors, opioid receptors, the serotonin transporter, and others. Its most significant effect that distinguishes it from the others is on GDNF: it's essentially a neurotrophic agent that also produces a profound altered state. Its pharmacology is complex enough that researchers are still mapping it.
The experience is different
Here's the practical difference.
MDMA therapy: 3 to 4 hours, typically with two therapists present, in a comfortable room, often with music. The patient can talk throughout. The therapists guide the session. Patients describe it as emotionally safe: difficult material feels accessible without being overwhelming.
Psilocybin therapy: 4 to 6 hours, with a similar therapeutic frame. Patients often lie down with eyeshades and music. There's typically not a lot of talking during the experience. Patients go inward. It can be challenging, but it rarely becomes what patients describe as grueling.
Ibogaine: 18 to 24 hours. The patient typically lies in a darkened room. There is no meaningful interaction with a therapist during the session. The experience is internal and largely out of the patient's control. It is frequently described as the most demanding experience of patients' lives. Not uncomfortable in a frightening way, necessarily. But intense, long, and not something you can reason your way through. You simply have to let it unfold.
The therapeutic model is different
Psilocybin therapy and MDMA therapy are explicitly built around the therapist-patient relationship. The preparation sessions, the dosing session with therapist presence, and the integration sessions form a coherent therapeutic arc. The medicine is part of the treatment, not the whole thing.
Ibogaine treatment at most clinics is, honestly, less structured around ongoing therapeutic relationship. The medicine is the primary vehicle. Integration support exists, but it is not yet consistently woven into the ibogaine program model the way it is in clinical psilocybin or MDMA trials.
This is changing. The better Mexico clinics are building more robust integration frameworks. But if you come to ibogaine expecting the structured therapeutic relationship of clinical psilocybin therapy, you may be surprised by how different the container is.
The patient population is different
Here's the most practical distinction: psilocybin and MDMA therapies primarily serve people dealing with depression, end-of-life anxiety, PTSD, and alcohol use disorder. Ketamine serves treatment-resistant depression. These are serious conditions, and the emerging evidence for these medicines is meaningful.
Ibogaine serves those populations too, particularly PTSD. But it is the only medicine in this category with a documented track record for interrupting opioid dependence and resetting the opioid receptor system. For someone in the grip of fentanyl addiction or years of opioid use disorder, ibogaine occupies a different position in the landscape than any of the others. It's not interchangeable.
Why this matters for your research
If you've read about the renaissance in psychedelic therapy and you're approaching ibogaine through that lens, expecting a guided, structured, therapeutically contained experience similar to what's been described in MAPS trials: you'll be better prepared if you understand the differences upfront.
The preparation, the medical requirements, the duration, the intensity, and the aftercare all differ from what most psychedelic therapy coverage describes. That's not a reason to avoid ibogaine. It's a reason to approach it on its own terms.